Explore 3 Stock Ideas & Industry Insights Download Free Report

Premium

BMO positive on Structure Therapeutics; expects stock price to shoot up by 40%

Broker BMO lifted its price target on drugmaker Structure Therapeutics (NASDAQ: GPCR). The stock has a mean recommendation rating of 1.4 on a scale of one to five. The consensus mean price target is US$81.80.

Akanksha Vashisht | 04 October 2023

J.P. Morgan upgrades DigitialBridge (NYSE: DBRG) to Overweight. Will other brokers follow suit

Broker J.P. Morgan raised its rating and price target on REIT firm DigitalBridge (NYSE: DRBG). The stock has a mean recommendation rating of 1.9 on a scale of one to five. The consensus mean price target is US$21.61.

Akanksha Vashisht | 28 September 2023

BTIG sees demand recovery for HPP’s studio business, sets target price at US$11 with Buy rating

Broker BTIG raised its price target on Hudson Pacific as the resolution of the ongoing actors’ strike is expected to draw in demand recovery for HPP’s studio business. After the increase, HPP’s share price surged 2.1% on September 26, 2023.

Akanksha Vashisht | 27 September 2023

Brokers upgrade price target on FedEx as Q1 earnings beat Street estimates

Brokers raise their price targets on FedEx as the company gains consumers from rival firms’ recent business slowdown. After this update, FDX’s share price surged 2.63% to US$267.97 on September 25, 2023.

Akanksha Vashisht | 26 September 2023

Brokers raise price target on Boston Scientific as it expects optimistic sales growth

Brokers BTIG, Needham and Stifel Nicolaus and Company raised their price targets on BSX. Boston Scientific expects sales in Q3 2023 to be 8.5% to 10.5% higher than that in Q3 2022.

Akanksha Vashisht | 22 September 2023

Mizuho positive on DoorDash, expects stock price to shoot up by 30%

Broker Mizuho upgraded food delivery firm DoorDash (NYSE: DASH) to ‘buy’ and raised its price target on DASH to US$105. The upgrade led to the company’s stock price rising by 2% on September 18, 2023.

Akanksha Vashisht | 19 September 2023

Wells Fargo upgrades Apellis to Overweight; stock up 45% in a month

Broker Wells Fargo upgraded pharmaceutical firm Apellis (NASDAQ: APLS) to ‘overweight’ and raised its price target on APLS to US$64. The upgrade led to the company’s stock price rising by 4.3% on September 15, 2023.

Akanksha Vashisht | 18 September 2023

BMO upgrades First Solar to Outperform after recent selloff

Broker BMO upgraded its rating on FSLR as it sees an attractive entry point in the stock after its recent weakness. FSLR had a mean recommendation rating of 2.2 and a consensus mean price target of US$246.01 as on September 14, 2023.

Akanksha Vashisht | 15 September 2023

TD Cowen expects strong holiday season for these off-price retailers, ups target price

TD Cowen raised its price target on off-price retail companies TJX and Ross Stores. TD Cowen raised its price target on TJX to US$99 and on ROST to US$137 on September 12, 2023.

Akanksha Vashisht | 13 September 2023

BofA upgrades ‘oversold’ Gilead Sciences (NASDAQ: GILD) to Buy

BofA raised its rating on pharmaceutical firm Gilead to ‘buy’ on September 8, 2023. The upgrade led the company’s stock price to rise by 3.3% on September 8, 2023.

Akanksha Vashisht | 11 September 2023
Support

Hi! How can we help you today?

Loading…